List view / Grid view
Neoantigens have gained much interest in recent years, mainly due to their ability to elicit a strong, specific immune response. Nikki Withers spoke to two immunology experts to explore the progress being made and assess what remains challenging for cancer investigators working on these transformational therapies.
This in-depth focus features articles on using combinations of immuno-oncology drugs to target solid tumours and haematological cancers and how neoantigens of cancer cells could be used as the basis of novel immuno-oncology vaccines.
In this issue authors discuss the development of COVID-19 antibody therapies, how high-throughput screening enhances research at the Crick Institute and why combinations of immuno-oncology drugs could revolutionise treatment of advanced cancers. Also included in the issue are articles on stem cells and imaging.
Chimeric antigen receptor (CAR) T-cell therapies have produced encouraging clinical outcomes, demonstrating their therapeutic potential in mitigating tumour development. However, another form of T-cell immunotherapy based on T-cell receptors (TCR) has also shown great potential in this field. Here, Nikki Withers speaks to Miguel Forte who elaborates on the process…
Researchers have shown that natural killer (NK) cells work best as an immunotherapy when in an early stage of development, so could be manufactured from pluripotent stem cells.
A study has shown that in mice, the GKT137831 drug makes tumours more sensitive to immunotherapy, so could be used to improve cancer treatments.
Researchers have created a method to activate CAR T cells with blue LED light to successfully combat solid tumours in mice.
Researchers have discovered that an antibody which targets the CD36 protein prevents Tregs from protecting tumours against immunotherapies in mouse models.
An innovative chimeric vaccine containing an Ebola gene that helps the virus evade the immune system has been used to selectively target and kill glioblastoma in mice.
A study has shown that T cells are driven to attack tumours by IL-2 and Blimp-1 in mice, which researchers say could form the basis of cancer therapies.
CAR T-cell therapy has caused quite a stir in the immunotherapy world, but it is a process that requires precision and care. Quantitative polymerase chain reaction (qPCR) has thus far been the stalwart technique for providing a check on copy numbers, but here Ping Jin explains why droplet digital PCR…
Monoclonal antibodies have shown great promise in the treatment of various cancers. This article discusses how therapeutic antibodies are produced and the various treatment strategies that are currently being adopted.
The landscape of cancer treatment has changed dramatically in the last seven years, beginning with the approval of Ipilmumab in 2011, the first immunotherapy drug. Efforts to unsheathe the tumour cells of their protective microenvironment and expose them to an active immune response have delivered several monoclonal antibodies (mAbs) that…
In this issue: AI-driven automated chemistry as a tool to accelerate drug discovery processes, the shifting landscape of immuno-oncology, and how lipid molecules provide an insight into biological research.
Combination therapy with a CHK1 or PARP inhibitor, with an immune checkpoint inhibitor caused the regression of small cell lung cancer in all mice treated...
